Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma

Inclusion Criteria: * Patients with histologically confirmed metastatic melanoma * Patients must have recovered from all side effects of their most recent systemic or local treatment for metastatic melanoma (grade ≤ 1). * At least one measurable brain metastasis between 5 mm and 35 mm in diameter, not previously treated with surgery and/or radiosurgery and located less than 5 cm from the skull * Patients may have received -or not- prior radiosurgery and/or surgery for brain metastases; if they have received prior local treatment, they must have at least 1new RANO and RECIST assessable brain metastases. * BRAF status wild type or mutated (and in that case previous treatment with BRAF inhibitor and MEK inhibitor allowed) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. * Age \>18 year * Hemoglobin ≥10g/dl * Platelets ≥ 100000mm3 * Neutrophils ≥1500/mm3 * Creatinine Clearance ≥ 50ml/mn * AST \<3N * ALT\<3N * Total bilirubin \<1.5N * Alkaline phosphatase \<3N * INR \< 1.5 * Prothrombin ≥70% * TCA \<1.2 * No Hepatocellular insufficiency * No unhealed wound on the head * No allergy to poly isoprene * Signed informed consent * Patient with health insurance coverage * Life expectancy \> 3 months Exclusion Criteria: * Patient previously treated by antiPD1 (except adjuvant antiPD1 therapy) * Ocular melanoma * Symptomatic or diffuse leptomeningeal involvement. * Symptomatic hemorrhagic brain metastases. * Symptoms of incoercible intracranial pressure; patients receiving corticosteroids and patients presenting intermittent seizures can be enrolled if they have a stable dose of corticosteroids (≤ 30mg/day corticotherapy) and anti-epileptic treatment since at least 2 weeks before enrolment. * Indication for urgent neurosurgery or radiotherapy * Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured or stage I untreated Chronic Lymphoid Leukemia. * Known human immunodeficiency viruses (HIV) infection and any ongoing infectious disease or significant background. * Concurrent administration of any anticancer therapies other than those administered in this study. * Treatment with any cytotoxic and/or investigational drug, antiCTLA4 or targeted therapy ≤ 4 weeks or \<5 half lives for targeted therapies or chemotherapy, prior to day 1 of study. * Prior whole brain radiotherapy